ARTICLE | Company News
Access Oncology Inc., Prescient deal
December 3, 2001 8:00 AM UTC
PRE signed a letter of intent to grant Access Oncology exclusive development and marketing rights, excluding Latin America and the Far East, to PRE’s anhydrovinblastine chemotherapeutic. PRE said it w...